ICER issues statement on the FDA’s approval of aducanumab for Alzheimer’s disease

7 June 2021 - The ICER believes that the FDA, in approving aducanumab (Aduhelm, Biogen) for the treatment of Alzheimer’s ...

Read more →

The economics of alternative payment models for pharmaceuticals

1 June 2021 - Pharmaceuticals are priced uniformly by convention, but vary in their degree of effectiveness for different disease indications.  ...

Read more →

External reference pricing: the drug pricing reform America needs?

27 May 2021 - External reference pricing, sometimes known as international reference pricing, refers to the practice of informing price negotiations ...

Read more →

ICER publishes protocol for first annual assessment of drug coverage policies that present barriers to fair access

25 May 2021 - ICER’s analysis, based on MMIT’s market access analytics solution, will evaluate how 15 of the largest ...

Read more →

Quality, access, and the use of real world data by payers: where are we now? Where do we want to be in the future?

15 May 2021 - One of the biggest challenges payers face today is determining the value of innovative therapies in diseases ...

Read more →

Making cancer treatments affordable today won’t hurt tomorrow’s innovation

12 May 2021 - Congress is about to debate legislation—the Lower Drug Costs Now Act (H.R.3)—that would give Medicare the ...

Read more →

ICER releases draft evidence report on therapies for atopic dermatitis

14 May 2021 - Public comment period now open until 11 June 2021; requests to make oral comment during public meeting ...

Read more →

ICER publishes final evidence report and policy recommendations on therapies for multiple myeloma

11 May 2021 - Independent appraisal committee unanimously determined the evidence is adequate to demonstrate that CAR-T treatments ide-cel and cilta-cel ...

Read more →

Rather than turning its back on the QALY, pharma should collaborate on efforts to improve it

7 May 2021 - A key element in the long-simmering debate on reining in drug prices in the United States ...

Read more →

ICER to assess treatment for severe asthma

6 May 2021 - Report will be subject of Midwest CEPAC meeting in November 2021; draft scoping document open to ...

Read more →

ICER releases draft evidence report on aducanumab for Alzheimer’s disease

5 May 2021 - Given the risk of side effects and the uncertainty of benefit, ICER assigns a draft rating of ...

Read more →

ISPOR launches HEOR solutions centre

27 April 2021 - New resource offers easy access to HEOR expertise from leading companies in the field. ...

Read more →

ICER publishes white paper evaluating policy options to strengthen FDA’s accelerated approval pathway for prescription drugs

26 April 2021 - Informed by expert input from patient groups, former regulators, payers, and life science companies, white paper analyses ...

Read more →

ICER publishes final evidence report and policy recommendations on therapies for lupus nephritis

16 April 2021 - For belimumab and voclosporin, independent appraisal committee votes highlight the importance of several potential benefits of both ...

Read more →

New recommendations on the critical appraisal of systematic reviews with cost and cost effectiveness outcomes

13 April 2021 - ISPOR announced today the publication of new guidance on how to evaluate the quality and risk ...

Read more →